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 Abstract 
 
The placenta is a temporary organ that is essential for a healthy pregnancy. It performs 
several important functions including the transport of nutrients, the removal of waste 
products and the metabolism of certain substances. Placenta disorders have been found to 
account for over 50% of stillbirths. Despite this there are currently no methods available to 
directly and non-invasively assess placenta function in utero. The primary aim of this pilot 
study is to investigate the use of 
1
H Magnetic Resonance Spectroscopy (MRS) for this 
purpose. 
1
H MRS offers the possibility to detect several placental metabolites including choline, lipids 
and the amino acids glutamine and glutamate (Glx) that are vital to fetal development and 
placental function. Here in utero placenta spectra were acquired from 9 small for gestational 
age (SGA) pregnancies, a cohort who are at increased risk of perinatal morbidity and 
mortality, and also from 9 healthy gestation matched pregnancies. All subjects were between 
26 and 39 weeks gestation. Placenta Glx, choline and lipids at 1.3 and 0.9ppm were 
quantified as amplitude ratios to that of intrinsic H2O. Wilcoxon Signed Rank tests indicated 
a significant difference in Glx/H2O (p = 0.024) between the two groups but not in 
choline/H2O (p=0.722) or in either lipid/H2O ratio (1.3ppm: p= 0.813, 0.9ppm: p=0.058).  
This study has demonstrated that 
1
H MRS has potential for detecting placental metabolites in 
utero. This warrants further investigation as a tool for monitoring placental function.  
  
 Introduction 
Disorders of the placenta are associated with over 50% of stillbirths (1). Despite this there are 
currently no methods available to non-invasively and directly assess placenta function in 
utero. Most information about this temporary yet crucially important organ has been gathered 
from post-delivery assessments, an exercise that has been likened to a post-mortem 
examination (2). There is an urgent clinical need to be able to monitor the function of the 
living placenta, as it supports the developing fetus, both to improve our understanding of this 
organ and to enable the effective identification and management of the at-risk fetus.  
There is potential value in the direct detection of placental choline, lipids and the amino acids 
glutamine and glutamate as they are all vital to placental metabolism and fetal development. 
These metabolites can be detected using 
1
H MRS but its application to the in utero placenta is 
novel. The primary aim of this pilot study is to investigate the use of 
1
H MRS for this 
purpose.  
Choline is essential for the normal function of cells, ensuring both structural integrity and 
signal functions of cell membranes and for influencing stem cell proliferation and apoptosis 
(3). The placenta delivers choline directly to the fetus but is also known to store large 
amounts of choline as acetylcholine (3). Lipids provide fuel for oxidative metabolism and are 
precursors for other compounds (4). They are delivered to the fetus in different ways e.g. via 
fatty acid binding proteins in the placenta (5). Glutamine and glutamate are important for 
fetal and placental nutrition and many other products are derived from them (6, 7). For 
example glutamine is involved in the synthesis of nucleotides and amino sugars required for 
the proliferation and differentiation of cells (6) and glutamate is a precursor of glutamine. 
The mother, placenta and the fetus are all involved in a delicate balance of the delivery and 
synthesis of glutamine and glutamate. The fetus receives glutamine from two sources, direct 
 transplacental transport from mother to fetus and glutamine synthesised within the placenta 
(7, 8). Glutamine is transported from the placenta to the fetus where it is used to synthesise 
glutamate in the fetal liver. The glutamate is then transported back to the placenta where it is 
converted back to glutamine (7). Day et al (8) suggest that placental glutamine and glutamate 
may also play a role in facilitating placental uptake of other amino acids and in passing waste 
products from the fetus to the mother. Therefore choline, lipids, glutamine and glutamate are 
known to be present in the placenta and their detection may have merit in the assessment of 
placental function.  
Small for gestational age (SGA) fetuses (defined as a birthweight less than the 10
th
 centile) 
are at increased risk of perinatal morbidity and mortality (9).  In SGA pregnancies, current 
obstetric management comprises fetal surveillance to try to predict fetal acidaemia thereby 
allowing timely delivery of SGA fetuses prior to irreversible end–organ damage and 
intrauterine fetal death. A wide range of tests including fetal biometry, biophysical profile 
(10), cardiotocograph (11), ultrasound assessment of amniotic fluid volume (12), and 
umbilical artery (13,14), middle cerebral artery (15), ductus venosus (16) and umbilical 
venous Doppler blood flow measurements (17) are used with varying efficacy. Despite 
reports in the literature indicating that placental function may be compromised in SGA 
pregnancies (18, 19), none of the currently available tests directly assess placental function in 
utero.  Here 
1
H MR spectra were acquired from the placenta of 9 SGA pregnancies and those 
of 9 healthy gestation matched subjects. The aim was to assess the ability of this technique to 
detect choline, lipids and the combined spectral contribution of glutamine and glutamate 
(Glx) in the placentae of these two groups.  
 
 
 Method 
Ethics statement 
The study was approved by Lothian Research Ethics Committee (11/SS/0031) and all 
participants gave written, informed consent.   
Study population 
Patients were enrolled at the Simpson Centre for Reproductive Health at the Royal Infirmary, 
Edinburgh, UK. Magnetic resonance studies were performed at the Clinical Research 
Imaging Centre in the Queen’s Medical Research Institute, University of Edinburgh, UK.  
9 women with a pregnancy complicated by SGA and 9 matched healthy controls were 
recruited prospectively. This is a pilot study and subjects were not derived from a larger 
cohort. Gestation was calculated from routine dating ultrasonography at 11-13 weeks 
gestation. To avoid bias, controls were prospectively recruited to match each recruited SGA 
pregnancy in turn for gestation (within 6 days) and smoking status. The inclusion criteria 
were a singleton pregnancy and >20 weeks gestation. The exclusion criteria were significant 
co-existing maternal systemic disease including microvascular disease, gestational diabetes, 
or contraindication to MRI. SGA was defined using ultrasound as an abdominal 
circumference <10
th
 centile (20) in accordance with Royal College of Obstetricians and 
Gynaecologists guidelines (9, 21).  SGA status was subsequently confirmed by a birthweight 
< 10
th
 centile. 
Doppler ultrasound scan 
All participants had a transabdominal ultrasound scan performed using a Toshiba Aplio XG 
system (Toshiba Medical Systems Ltd, Crawley, UK) to assess fetal size, liquor volume and 
umbilical artery Doppler blood flow. Fetal size was assessed measuring head circumference 
 and abdominal circumference.  Liquor volume was assessed subjectively with the amniotic 
fluid index being calculated if subjective assessment was abnormal.  A free loop of the 
umbilical cord was interrogated with colour flow then pulsed Doppler in order to determine 
the resistance index. Centile charts for gestational age for Scottish singleton births were used 
to calculate birth weight percentiles (22).  
1
H MRS Acquisition 
All MR spectra were acquired using a wide-bore 3T MR Verio system (Siemens Healthcare 
Sector, Siemens AG, Erlangen, Germany). To avoid vena-cava compression, women were 
placed in a left-lateral tilt, with blood pressure being constantly monitored using a Veris MR 
Vital Signs Monitor (Medrad, UK). No fetal sedation was used and each participant was 
limited to spending 45 minutes in the scanner. Placenta location and orientation was 
confirmed using standard half-Fourier rapid MRI acquisitions and used to spatially select the 
MRS voxel. No other structural MR scans were acquired. A single voxel point resolved 
spectroscopy (PRESS) technique was applied with TR/TE =1500ms/30ms, 96 signal 
averages, bandwidth of 2000Hz and a water suppression bandwidth of 50Hz. Each spectral 
acquisition took 2 minutes 30 seconds. Signal was received from selected elements of the 
spine matrix coil and body matrix surface coils positioned to allow adequate coverage of 
placenta. Following the acquisition of scout images, the scanner bed was moved to ensure 
that placenta was positioned at isocentre and great care was taken to position the 
20×20×40mm
3
 voxel within the placenta and to avoid any contaminant signal from 
surrounding tissue. An example of voxel positioning for MRS acquisition is shown in Figure 
1. An optimised semi-automated shimming protocol was systematically applied until the full 
width at half maximum of the water peak was <30Hz. Significant movement of the placenta 
is not expected during spectral acquisition and data were acquired with the mother free 
breathing throughout.  
 Spectral analysis 
All spectral analysis was carried out using jMRUI (23). Water peak amplitudes were first 
estimated for each spectrum using the advanced method for accurate, robust and efficient 
spectral fitting (AMARES) a semi-automatic quantification method (24). Analysis of 
overlapping in utero placenta spectral components was then carried out using the Quest 
algorithm (23, 25). The Quest algorithm is a time domain spectral analysis tool which 
estimates metabolite amplitudes using a non-linear least squares fit of a weighted 
combination of simulated metabolite signals to the acquired spectrum. As recommended in 
the literature (25), the intrinsic water peak was removed using the Hankel Lanczos Singular 
Values Decomposition Filter (HLSVD) prior to metabolite quantification. For this purpose a 
metabolite basis set was generated using the NMR-Scope function also available in jMRUI 
(25) and included contributions from the overlapping resonances of glutamine and glutamate 
(Glx) between 2.06-2.44ppm and between 3.76-3.78ppm, from choline (3.2, 3.53 and 
4.08ppm) and fatty acids (1.3 and 0.9ppm). Separate simulations of glutamine and glutamate 
were generated and then summed using the jMRUI pre-processing tool to create a simulation 
of Glx. The Quest algorithm calculates errors associated with the estimated metabolite 
amplitudes using an extended version of the Cramer-Rao lower bounds calculation (25). The 
errors for each of the calculated metabolite ratios were derived through error propagation of 
this jMRUI output. The Quest algorithm carries out a reproducible estimation and subtraction 
of the baseline and has previously been subject to extensive Monte Carlo studies that have 
validated its reliability with respect to bias and variance (25). 
 
An example of the Quest algorithm output for SGA subject 5 is shown in Figure 2. This 
shows the acquired spectrum (Figure 2a), the estimated spectrum (Figure 2b), the simulations 
of individual metabolites (Figure 2c) and the residue function (Figure 2d) following fitting of 
 the estimated spectrum to the acquired spectrum. Glx, choline and both lipid peaks at 1.3ppm 
and 0.9ppm were quantified in terms of ratios to the amplitude of the intrinsic water peak (i.e. 
Glx/H2O, choline/H2O, Lipid 1.3ppm/H2O and Lipid 0.9ppm/H2O).  
 
 Statistical tests 
The null hypotheses are that no differences exist between the following metabolite ratios of 
matched SGA and control placentae: 1) Glx/H2O; 2) choline/H2O; 3) Lipid contribution at 
1.3ppm (Lipid 1.3ppm/H2O); and 4) Lipid contribution at 0.9ppm (Lipid 0.9ppm/H2O). Not 
all metabolite ratio differences conformed to a normal distribution. Therefore separate 
Wilcoxon Signed Rank tests were carried out on paired differences of each of the four 
metabolite amplitude ratios using Minitab ® 16 Statistical Software (Minitab, Inc. 
www.minitab.com). Significance was defined as p<0.05.  
Results 
Demographics of study population 
Mean maternal age range was 28.5 ± 7.6 years and mean maternal body mass index (BMI) 
was 23.3 ± 6.0 kg/m
2
.  The maternal demographics and the population characteristics at 
delivery are shown in Table 1.  
Perinatal outcome 
Perinatal outcomes are demonstrated in Table 2.  All SGA subjects were confirmed by a 
birthweight of <10
th
 centile. Five out of the nine SGA subjects delivered preterm (defined as 
<37 weeks gestation), whereas all controls delivered at term. All controls and seven out of 
nine SGA subjects were discharged home alive and well. One SGA subject was stillborn and 
one had a neonatal death following surgery for gastroschisis. Three SGA subjects were 
 admitted to the neonatal unit (NNU), two following surgery for gastroschisis and one due to 
low temperature and hypoglycaemia secondary to low birthweight. Two controls were 
admitted to the NNU, one due to suspected sepsis and the other following an unplanned home 
delivery. Other than the two SGA subjects with gastroschisis, all other controls and subjects 
had no genetic or structural abnormalities.  
1
H MRS 
In utero 
1
H MRS of the placenta were obtained in all 9 SGA pregnancies and in all 9 healthy 
control subjects.  The spectrum acquired from control 6 is shown in Figure 3. In Figure 3a the 
water peak is dominant at 4.7ppm and in Figure 3b the water peak has been filtered out to 
reveal the smaller amplitude metabolite peaks. Spectral peaks corresponding to choline, Glx 
and lipids are indicated.  The amplitude ratios of choline, Glx and the lipid peaks at 1.3ppm 
and 0.9ppm to the intrinsic water peak at 4.7ppm (i.e. Choline/H2O, Glx/H2O, Lipid 
1.3ppm/H2O, Lipid 0.9ppm/H2O) are shown in Table 3. 
 No significant difference in paired SGA-control placental choline/H2O ratios was found 
(p=0.722). This suggests that placental choline metabolism is preserved in this SGA cohort.  
A significant difference (p=0.024) was found between paired SGA-control placental Glx/H2O 
ratios, suggesting that Glx metabolism is altered in this cohort. Finally the amplitude ratios of 
Lipid 1.3ppm/H2O and Lipid 0.9ppm/H2O did not demonstrate a significant difference 
between matched SGA-control pairs (p=0.813 and p=0.058 respectively).  
Discussion 
To our knowledge, this is the first in utero placenta 
1
H MRS study to assess choline and lipid 
using the internal water peak as an independent reference and to additionally assess placental 
glutamine and glutamate as it supports the developing fetus. This study has shown that the 
 Glx/H2O ratios of the SGA placentae and gestation-matched healthy control placentae were 
significantly different but that their choline/H2O and lipid/H2O ratios were not. This suggests 
that in this cohort of SGA placentae, metabolism of Glx is altered but that choline and lipid 
metabolism is preserved.   
The finding that placental Glx is significantly reduced in a cohort of 9 SGA subjects is 
consistent with other studies in the literature. Firstly there are general reports of a reduction in 
most essential amino acid concentrations in the SGA fetus prior to delivery (26, 27). There 
are also reports of a reduction in the amino acid transport mechanisms of the placenta in SGA 
pregnancies (18, 19). More specifically, in an ovine fetal growth restricted model Regnault et 
al (28) found that there was a significant reduction in the umbilical uptake of glutamine and 
in the placental uptake of fetal glutamate. Hill et al (29) identified 3 different transport 
mechanisms in vitro that allow glutamine uptake across the microvillous plasma membrane 
(MVM) of the placenta. They report that the majority of NA
+
-dependent and NA
+
-
independent transport of glutamine across the MVM was mediated by mechanisms that are 
known to be reduced in fetal growth restriction (FGR) pregnancies, a severely compromised 
subset of SGA pregnancies.  
As previously described (7), the mother, placenta and the fetus all form part of a delicate 
glutamine-glutamate shuttle. Glutamine is both transported across the placenta from the 
mother and is also manufactured in the placenta (6-8), using glutamate which is synthesised 
in the fetal liver. Therefore any disruption in the supply or transport mechanism of either 
amino acid from any one source could potentially disrupt this fine balance of placental Glx 
metabolism. It is known from studies in the porcine placenta (6) that both glutamine and 
glutamate vary with gestational age. However, by limiting analysis to comparisons of SGA-
control pairs matched to gestational age, the influence of gestation on glutamine and 
glutamate is removed.  
 The Glx/H2O ratio was found to be reduced in 7 of the SGA subjects (Table 3) compared to 
their matched control but was increased in 2 subjects (SGA 4 and 7) compared to their 
matched controls. These subjects also had reversed end diastolic flow (REDF) and raised 
flow in their umbilical artery respectively. It is beyond the scope of this article to make 
conclusions regarding clinical outcomes but it should be noted that SGA subject 4 was 
stillborn 10 days after MRS acquisition. Therefore it is likely that placental metabolism was 
significantly altered in this case.  Regnault et al (28) report that even in the most severe SGA 
cases where FGR is confirmed, the fetus is not consistently in a state of constant hypoxia and 
so may have access to higher concentrations of amino acids at different times. Their work 
indicates that in severe SGA with FGR there is a reduction in placental O2 transport which 
reduces fetal metabolism. They suggest that this reduction in metabolic rate may be greater 
than the reduction in placental amino transport capacity, leading to normal or higher than 
normal amino acid concentrations. It is possible that this mechanism may account for the 
relative increase in Glx/H2O ratios in SGA subjects 4 and 7 compared to their respective 
control subjects.  
This study found that there were no significant differences in choline/H2O ratios between 
SGA placentae and matched control placentae. Choline is vital for normal brain development, 
including the prevention of neural tube defects (3). Choline passes from mother to fetus via 
the placenta against a concentration gradient and both fetal tissue and amniotic fluid have 
very high choline concentrations compared to maternal levels (3).  Despite this there is 
evidence that reproductive age women are relatively resistant to choline deficiency due to an 
oestrogen driven process to produce phosphatidylcholine from precursors in the liver (3, 30). 
The importance of choline to fetal neurodevelopment and the different reserves that the 
mother can use to supply choline to the fetus could perhaps explain the preserved choline 
levels in SGA placentae compared to controls found in this study.   
 Individual SGA subjects 4, 5 and 7 had increased choline compared to their matched control 
subject. As discussed above SGA subjects 4 and 7 had REDF and raised flow in the umbilical 
artery respectively.  Subject 5 also had raised umbilical artery flow.  This anecdotal finding is 
consistent with previous larger studies (31, 32) that have measured choline concentrations in 
venous umbilical cord blood samples in SGA and normal pregnancies. Venous blood samples 
reflect maternal choline concentrations, maternal-placental choline transfer and placental 
choline metabolism as opposed to arterial blood samples that reflect fetal metabolism (31). 
Although both studies hypothesised that a status of SGA and subsequent low birth weight 
would result in low choline levels, in fact they observed high choline concentrations in the 
umbilical cord blood samples of these neonates. Hogeveen et al (31) suggested two reasons 
for this. The first is that high choline concentrations reflect low choline consumption by the 
fetus and the second is the potential that slow fetal growth triggers an increased placental 
transport of choline.   
Assessment of the Lipid 1.3ppm/H2O ratios, the dominant lipid peak, of individual SGA-
control pairs showed that there was an increase for SGA subjects 5, 7 and 9 compared to their 
control subject. These subjects all had raised umbilical artery Doppler ultrasound 
measurements. Interestingly 2 of these SGA subjects also had increased placental 
choline/H2O ratios. Choline is a precursor for the phospholipid phosphatidylcholine, a main 
constituent of membranes, lipoproteins, bile and surfactants (33). Therefore it is possible that 
placental choline and lipid metabolism are related. 
A previous study (34) demonstrated a reduction in the placental choline/lipid ratio using in 
vivo 
1
H MRS, acquired with TE 144ms, in 3 pregnancies complicated by severe SGA with 
FGR. All subjects in that study in that study had reduced liquor volume and absent end 
diastolic flow in the umbilical artery. That study speculated that this may be a biomarker of 
critical placental failure indicated by reduced cell turnover. These subjects were recruited as 
 their placental function was known to be severely compromised and were confirmed to be 
suffering from placental mediated FGR. Conversely the present study concerns pregnancies 
not confirmed to be suffering from FGR. Spectra were acquired using a lower TE of 30ms 
allowing the detection of Glx in addition to choline and lipid. Significant differences were not 
detected between the choline/lipid 1.3ppm ratios (Wilcoxon signed rank test p= 0.286, level 
of significance p<0.05) or the choline/lipid 0.9ppm ratios (p=0.155) of SGA placentae and 
those of matched controls (data not shown). This was expected following confirmation that 
no significant differences were observed in choline/H2O ratios or either of the lipid/H2O 
ratios between these groups. It was also expected that as these two studies considered 
subjects with different clinical characteristics, their choline and lipid metabolisms would be 
different. In the future it would be of interest to assess placental Glx/H2O ratios in known 
cases of severe FGR.  
Mckelvey and Kay (35) carried out a review of MRS studies of the placenta. Of these studies 
only 2 applied 
1
H MRS to study ex vivo placental tissue samples. Serkova et al (36) 
calculated absolute placental concentrations of major cellular metabolites including 
glutamine, glutamate, phosphocholine, glycerophosphocholine and lipids in extracts of 
normal placenta collected at different time points following delivery. Pulkkinen et al (37) 
found that normal ex vivo placenta samples had higher phospholipid content than normal 
myometrium tissue samples. The only in vivo study reported was by Weindling et al (38) who 
acquired 
31
P MR spectra on a 1.5T scanner from an anteriorly placed placenta in 7 women 
with normal pregnancies. Therefore there is currently no opportunity to directly compare the 
results from the present study to any other published data.  
We accept that the acquired in utero placenta spectra may contain overlapping contributions 
from different metabolites. Therefore it is to be expected that spectral resolution will be lower 
than is possible in ex vivo studies. Previous ex vivo and in vivo studies have attributed 
 metabolite peaks detected at ~ 2 parts per million (ppm) to Glx (39, 40). However one 
possible contaminant may simply be polyunsaturated fatty acids (41). In addition Takeuchi et 
al (42) suggested that a peak detected at ~2ppm in a 
1
H MRS study of ovarian tumours could 
be attributed to N-acetyl mucinous compounds (i.e. those containing the glycosylated protein 
mucin). There is evidence in the literature that mucin-15 is expressed in the human placenta 
to varying degrees at different stages of gestation (43), but equally there is evidence that 
glutamine is present in ovarian tumours (44). Takeuchi et al (42) concede that their results 
also suggest contamination from other sources. Using a powerful spectral analysis tool such 
as the Quest algorithm is imperative to allow contributions form overlapping spectral 
metabolites to be quantified.   
This study is limited by its small sample size and heterogeneity in demographics and clinical 
characteristics of study participants. There is no evidence that factors such as maternal age, 
BMI and parity would influence the results. All but one of the control subjects had an 
abdominal circumference above the 50
th
 centile. Although control subjects were not 
selectively recruited to have abdominal circumferences above the 50
th
 centile, this may 
potentially influence observed placental metabolite differences between SGA and control 
subjects. Two of the fetuses had gastroschisis. There is evidence that placental dysfunction is 
an important causative factor in cases of SGA with gastroschisis (45). However, we accept 
that other factors will also play a role in causing SGA in fetuses with gastroschisis and that 
this may be a potential limitation in the SGA group. Four SGA subjects had abnormal 
umbilical artery flow measurements. It is known that umbilical artery Doppler ultrasound 
measurements are often normal in the SGA fetus (46, 47). This study did not aim to and was 
not powered to detect differences in placental metabolites in SGA pregnancies with and 
without evidence of abnormal Doppler measurements. However in future studies it would be 
preferable to sub-classify subjects into groups of normal and abnormal Doppler 
 measurements. The application of 
1
H MRS to study the in utero placenta requires specialist 
knowledge and so may not be immediately transferrable to all centres or all patients. Future 
studies would benefit from acquiring placental volume scans which could then be assessed 
for correlation with metabolite ratios.  
In conclusion, this study suggests that 
1
H MRS can be used to detect placental metabolites in 
utero.  We have demonstrated an ability to detect significant differences in Glx in the 
placentae of SGA pregnancies in utero and can demonstrate maintained choline and lipid 
levels in these pregnancies. Although these findings cannot currently be used to inform 
clinical decisions, these encouraging initial results indicate that 
1
H MRS warrants further 
investigation in the assessment of in utero placental function. This is a new application of an 
established technique and in the first instance further tests in larger populations are required 
to confirm these results.   
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 Table 1: Maternal demographics 
Subject Gestational age at 1H 
MRS (weeks 
+days
) 
Smoker (Y/N) Age Parity BMI  Abdominal circumference 
ultrasound centile 
Umbilical 
artery flow 
Liquor volume  
         
SGA 1 33
+3
 N 36 1+0 19 5
th
  Normal Reduced 
Healthy 1 33
+4
 N 33 0+0 24.2 25
th
 -50
th
  Normal Normal 
         
SGA 2 33
+2 
Y 32 1+0 18.3 <5
th
  Normal Normal 
Healthy 2 33
+5
 Y 18 0+0 18.7 50
th
 – 95th  Normal Normal 
         
SGA 3 29
+2
 Y 26 2+3 23.6 5
th
  Normal Reduced 
Healthy 3 29
+3
 Y 20 0+0 19.5 75
th
  Raised Normal 
         
SGA 4 26
+0
 N 41 0+0 39.7 <5
th
  REDF Normal 
Healthy 4 26
+6
 N 24 1+1 30.5 75
th
  Normal Normal 
         
SGA 5 36
+6
 N 26 1+1 23.1 5
th
  Raised Normal 
Healthy 5 36
+1
 N 38 0+2 18.8 95
th
  Normal Normal 
         
SGA 6 31
+4
 N 27 0+0 19.8 5
th
 – 10th  Normal Normal 
Healthy 6 32
+0
 N 39 2+0 20.9 95
th
  Normal Normal 
         
SGA 7 37
+3
 Y 28 2+1 30.2 <5
th
  Raised Normal 
Healthy 7 38
+2
 Y 22 2+0 23.7 25
th
  Normal Normal 
         
SGA 8 33
+5
 N 18 0+0 19.2 <5
th
 Normal Normal 
Healthy 8 33
+3
 N 28 1+0 20.7 95
th
 Normal Normal 
         
SGA 9 28
+5
 N 33 0+0 23.0 5
th
-10
th
 Raised Normal 
Healthy 9 29
+2
 N 35 1+1 20.3 95
th
 Normal Normal 
         
 
 Table 2: Perinatal outcome. Abbreviations: HFFD Haag Ferguson Forceps Delivery; SVD Spontaneous Vertex Delivery; EmCS Emergency 
Caesarean Section; NNU Neonatal Unit; RDS Respiratory Distress. 
Subject Time between MRI 
and delivery (days) 
Gestational age at 
delivery (weeks
+days
) 
Mode 
delivery 
Sex  Birthweight (g) Percentile at 
birth  
Outcome  
SGA 1 46 40
+1
 SVD F 2610 <2
nd
  Alive and well 
Healthy 1 44 39
+6
 HFFD M 2960 9
th
 - 25
th
  NNU admission for 5 days with suspected 
sepsis. Alive and well 
        
SGA 2 23 36
+4
 SVD M 1610 <2
nd
  Gastroschisis, surgery, neonatal death 11 
days of age 
Healthy 2 45 40
+1
 SVD M 3420 25
th
 -50
th
  NNU admission for 2 days with RDS 
following unplanned home delivery. Alive 
and well 
        
SGA 3 44 35
+4
 EmCS F 1690 2
nd
  Gastroschisis surgery, alive and well.  
Healthy 3 83 41
+1
 SVD F 3640 50
th
 – 75th  Alive and well 
        
SGA 4 10 27
+3
 EmCS F 500 <2
nd
  Stillbirth 10 days after MRI scan 
Healthy 4 102 40
+3
 SVD F 3650 50
th
 -75
th
  Alive and well 
        
SGA 5 2 37
+0
 EmCS F 1840 <2
nd
  Alive and well 
Healthy 5 24 39
+4
 SVD M 4020 91
st
  Alive and well 
        
SGA 6 40 37
+2
 EmCS F 1710 <2
nd
  NNU admission for 5 days with low 
temperature and hypoglycaemia. Alive and 
well 
Healthy 6 53 39
+4
 SVD F 3670 75
th
 – 91st  Alive and well 
        
        
SGA 7 4 38
+1
 EmCS F 1980 <2
nd
   Alive and well 
Healthy 7 9 39
+4
 SVD M 3170 25
th
  Alive and well 
        
SGA 8 3 34
+1
 ElCS M 1670 <9
th
 Alive and well 
Healthy 8 56 41
+3
 SVD F 3500 25
th
 - 50
th
 Alive and well 
        
SGA 9 42 34
+5
 EmCS M 1570 <2
nd
 Admitted to NNU, RDS for 21 days. Alive 
and well 
Healthy 9 81 39
+6
 SVD M 3890 75-91
st
 Alive and well 
        
 Table 3: Placenta amplitude ratios of Glx/H2O, Cho/H2O and Lipid 1.3ppm/H2O for SGA and gestation matched healthy controls quantified 
from placenta 
1
H MR spectra using jMRUI. Standard deviations, derived through error propagation of those estimated by jMRUI, are also 
quoted. H2O refers to the intrinsic water peak of each individual spectrum observed at 4.7ppm.  N/A indicates that the metabolite was not 
detected and * indicates that the amplitude ratio for the SGA placenta is higher than that of the matched control.  Wilcoxon signed rank test p 
values (significance < 0.05) are quoted for SGA-healthy subject comparisons for each ratio.  
 
 
    
 
 
 
 
                            Metabolite amplitude ratios ± stdev 
                                                                      Glx/H2O (×10
-3
)                                                  Choline/H2O (×10
-3
) 
Matched Pairs    SGA Healthy SGA Healthy 
SGA 1 /Healthy 1 1.42 ± 0.02 2.85 ± 0.04           0.50 ± 0.01 0.80 ± 0.08 
SGA 2 /Healthy 2 0.68 ± 0.02 1.83 ± 0.05 0.18 ± 0.05 0.31 ± 0.13 
SGA 3 /Healthy 3 0.47 ± 0.01 3.66 ± 0.04 0.52 ± 0.01 0.69 ± 0.10 
SGA 4 /Healthy 4   2.67 ± 0.03* 2.38 ± 0.06   0.63 ± 0.02*  0.36 ± 0.10 
SGA 5 /Healthy 5 6.48 ± 0.07 9.76 ± 0.10   1.36 ± 0.17* 0.81 ± 0.18 
SGA 6 /Healthy 6 0.89 ± 0.03 3.08 ± 0.06 0.53 ± 0.11 0.83 ± 0.04 
SGA 7 /Healthy 7   2.44 ± 0.09* 1.38 ± 0.03   0.83 ± 0.14* 0.38 ± 0.08 
SGA 8 /Healthy 8 0.28 ± 0.08 2.12 ± 0.04 0.61 ± 0.22 0.74 ± 0.03 
SGA 9 /Healthy 9 4.00 ± 0.08 5.39 ± 0.06 1.07 ± 0.22 0.90 ± 0.03 
p-value  0.024  0.722 
                                                              Lipid 1.3ppm/H2O (×10
-3
)                                          Lipid 0.9ppm/H2O (×10
-3
) 
Matched Pairs SGA Healthy SGA Healthy 
SGA 1 /Healthy 1 3.27 ± 0.41 7.59 ± 0.53 3.84 ± 0.10 5.43 ± 0.25 
SGA 2 /Healthy 2 0.96 ± 0.27 8.17 ± 0.59 0.44 ± 0.08 5.99 ± 0.23 
SGA 3 /Healthy 3 3.50 ± 0.37 8.51 ± 0.68 3.87 ± 0.08 5.08 ± 0.20 
SGA 4 /Healthy 4 0.68 ± 0.39 2.78 ± 0.63 2.52 ± 0.15 2.61 ± 0.88 
SGA 5 /Healthy 5  44.9 ± 1.35* 16.5 ± 1.34 11.9 ± 0.37 36.6 ± 1.37 
SGA 6 /Healthy 6 5.69 ± 0.74 15.1 ± 0.91 5.63 ± 0.19 7.69 ± 0.22 
SGA 7 /Healthy 7  43.8 ± 1.46* 6.83 ± 0.40   6.70 ± 0.48* 2.54 ± 0.13 
SGA 8 /Healthy 8 4.62 ± 1.58 4.32 ± 0.62 N/A 3.33 ± 0.20 
SGA 9 /Healthy 9  23.1 ± 1.82* 8.72 ± 0.87 2.94 ± 0.34 9.83 ± 0.29 
p-value  0.813  0.058 
